A 35-year-old woman on warfarin for atrial fibrillation presents with recurrent epistaxis over the past 3 days. INR is 8.2 (therapeutic range 2–3). On examination, bleeding is from the anterior nasal septum (Kiesselbach's area). Hemoglobin is 9.8 g/dL (previously 12.5 g/dL). What is the most appropriate immediate management?

Explanation

## Anticoagulation-Related Epistaxis: Reversal and Hemostasis ### Clinical Context **Key Point:** Supratherapeutic INR (8.2) with active bleeding requires **immediate reversal** using both vitamin K (slow, 12–24 hours) and fresh frozen plasma (FFP) or prothrombin complex concentrate (PCC; faster, 30 minutes) to achieve rapid hemostasis [cite:Harrison 21e Ch 182]. ### INR Reversal Strategy | INR Level | Bleeding Status | Management | |-----------|-----------------|-------------| | 2–3 | None | Continue warfarin | | 3–5 | None | Reduce dose or skip 1 dose | | >5 | None | Vitamin K 2.5–5 mg IV (slow onset) | | >5 | **Active bleeding** | **Vitamin K + FFP/PCC (immediate)** | | Any | **Life-threatening bleeding** | **PCC + Vitamin K (preferred over FFP)** | **High-Yield:** - **Vitamin K (phytonadione):** Restores synthesis of factors II, VII, IX, X. Onset 12–24 hours. Dose: 2.5–5 mg IV (slow infusion, not bolus — risk of anaphylaxis). - **Fresh Frozen Plasma (FFP):** Contains all vitamin K–dependent factors. Onset <30 minutes. Dose: 10–15 mL/kg (typically 3–4 units). **Disadvantage:** volume overload, slower than PCC. - **Prothrombin Complex Concentrate (PCC):** Concentrated factors II, VII, IX, X. Onset <30 minutes. **Preferred over FFP** for life-threatening bleeding (faster, less volume). Not widely available in India; FFP is practical alternative. ### Management Algorithm ```mermaid flowchart TD A[Supratherapeutic INR + Active Bleeding]:::urgent --> B[Secure airway, IV access, type & cross]:::action B --> C[Administer FFP 3-4 units or PCC if available]:::action C --> D[Administer Vitamin K 2.5-5 mg IV slowly]:::action D --> E[Recheck INR in 4-6 hours]:::action E --> F{INR normalized to 2-3?}:::decision F -->|Yes| G[Perform cautery or anterior packing]:::action F -->|No| H[Repeat FFP/PCC dose]:::action G --> I[Resume warfarin at lower dose after hemostasis]:::action ``` ### Local Hemostasis for Anterior Epistaxis 1. **Topical hemostatics:** Epinephrine (1:10,000), thrombin, tranexamic acid (TXA). 2. **Cautery:** Silver nitrate or electrocautery — **only after INR is normalized** to prevent recurrent bleeding. 3. **Anterior packing:** If cautery fails or patient unstable. **Clinical Pearl:** Do NOT cauterize while INR is supratherapeutic — the bleeding vessel will reopen once the cautery eschar sloughs. Wait for INR to normalize (typically 24–48 hours after FFP + vitamin K). ### Why Stop Warfarin? - This patient has **active bleeding** from a supratherapeutic INR. - Continuing warfarin would worsen coagulopathy and prolong bleeding. - Warfarin can be restarted at a **lower dose** once hemostasis is achieved and INR is therapeutic (2–3). - Atrial fibrillation remains a stroke risk; do not leave the patient anticoagulation-free for >24 hours if possible. **Mnemonic for Warfarin Reversal:** **VITAMIN K + FFP** - **V**itamin K (slow, 12–24 hrs) - **I**nternational Normalized Ratio (check baseline and recheck at 4–6 hrs) - **T**ransfusion (FFP or PCC for immediate reversal) - **A**ctive bleeding? (use FFP/PCC; vitamin K alone is too slow) - **M**onitor INR and clinical response - **I**nfusion rate (vitamin K: slow IV, not bolus) - **N**ormalize INR to 2–3 before definitive hemostasis - **K**eep patient on lower warfarin dose post-reversal